By Dr. Harriet Kamendi, PhD – Regulatory Toxicologist & CEO, Kandih BioScience

 The Signal That Shouldn’t Have Been Missed

In November 2025, the CDC confirmed an active multistate outbreak of infant botulism linked to powdered infant formula — affecting infants across at least 10 U.S. states.
(CDC
, Los Angeles Times
, PR Newswire
)

The implicated product: two recalled lots of ByHeart Whole Nutrition Infant Formula.

For toxicologists, regulatory scientists, and product developers, this isn’t just another recall — it’s a wake-up call.

 Toxicology must be embedded in infant-formula design — not just for chemical safety, but for microbial and process-related toxins that can turn nutrition into neurotoxin exposure.

 Why This Outbreak Matters to Toxicology & Product Development
1. Infant Botulism Is a Toxicologic Event — Not Just a Microbial One

Though caused by a microbe (Clostridium botulinum), infant botulism is fundamentally a toxin-mediated disease.
The bacterium produces botulinum neurotoxin, which blocks acetylcholine release at nerve terminals, causing flaccid paralysis and potentially fatal respiratory failure.
(CDC Clinical Overview, 2024
)

When powdered formula becomes contaminated with spores, it transforms from a food exposure into a toxic exposure event.

Toxicologists must evaluate not only whether spores survive, but how the formula matrix, manufacturing environment, and infant gut physiology influence toxin activation and uptake.

2. Processing + Formulation Risks That Hide in Plain Sight

Infant formula development often focuses on nutritional composition — amino acids, fats, micronutrients — and compliance with 21 CFR Part 106.

But this outbreak exposes what’s often missing:

Spore survival kinetics under drying or pasteurization

Recontamination risks post-processing

Toxin formation potential during storage or reconstitution

According to The Los Angeles Times
, affected infants consumed formula before symptoms developed — suggesting spore persistence or toxin presence despite standard sterilization.

From a regulatory toxicology perspective, this means risk assessment must cover both chemical and biological pathways of toxicity.

3. Regulatory Toxicology & Lifecycle Oversight

The FDA’s Food Safety Modernization Act (FSMA) emphasizes preventive controls, but “prevention” must include toxicological endpoints, not just microbial ones.
Toxicology provides the framework to:

Define hazard thresholds and exposure limits for toxins in vulnerable populations (infants).

Establish toxin dose-response models for neurotoxins.

Set Acceptable Daily Intakes (ADI) for incidental exposures.

Product developers must build design controls that integrate toxicology into formulation, packaging, and process validation — not just at final testing.

 Practical & Tactical Points for Product Development Teams

 Perform Spore and Toxin Simulation Studies

Test how C. botulinum spores survive or die across processing, storage, reconstitution, and feeding conditions.
Model toxin kinetics using real-world temperature and humidity profiles.

 Define Toxicological Hazard Thresholds

Collaborate with microbiologists to set maximum allowable toxin loads per serving, grounded in neurotoxicity data specific to infant physiology.

 Incorporate Early Hazard Mapping

Ask toxicology-driven questions during design:

Which raw materials or packaging could reintroduce spores?

How do pH, oxygen exposure, and reconstitution temperature influence toxin activation?

 Establish Sentinel Surveillance Systems

Track post-market adverse events tied to formula lots.
Feed toxicology data into exposure models to detect early signals before they reach outbreak scale.

 Build Cross-Disciplinary Teams

Ensure formulation scientists, process engineers, QA/QC, microbiologists, and toxicologists collaborate from concept to commercialization.
Safety is a system — not a department.

 My Take: A Wake-Up Call Toxicology Needs to Own

This outbreak is not a “food safety issue.” It’s a product development failure that sidelined toxicology until after the crisis.

Too often, toxicologists are brought in as final reviewers rather than design partners.
But in infant nutrition — where dose, exposure, and vulnerability intersect — there’s no margin for error.

The next generation of formula safety must treat every ingredient, every process, and every packaging decision as a potential toxicologic variable.
Otherwise, we’re not making safe products — we’re making safe assumptions.

 The Bottom Line

Toxicology matters for infant formula just as much as it does for pharmaceuticals.
When infants are exposed to spore-borne neurotoxins through a consumer product, the result isn’t a “manufacturing deviation” — it’s a toxicologic event.

For innovators, regulators, and QA leads, the message is clear:

 Build safety into every layer — don’t test it at the end.

 References

1. Centers for Disease Control and Prevention (CDC). Outbreaks and Investigations – Infant Botulism Outbreak Linked to Infant Formula, Nov 2025. https://www.cdc.gov/botulism/outbreaks-investigations/infant-formula-nov-2025/investigation.html

2. Marler Clark, The Food Safety Law Firm. Botulism Alert: ByHeart-brand infant formula linked to 13 illnesses in 10 states, Nov 2025. https://www.prnewswire.com/news-releases/botulism-alert-byheart-brand-infant-formula-linked-to-13-illnesses-in-10-states-302609384.html

3. U.S. Food and Drug Administration (FDA). Infant formula recall investigation: ByHeart Whole Nutrition Infant Formula, Nov 2025. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/response-broader-fda-investigation-byheart-initiates-voluntary-recall-two-batches-infant-formula

4. CDC. Clinical Overview of Infant Botulism, Apr 2024. https://www.cdc.gov/botulism/hcp/clinical-overview/infant-botulism.html

5. Food Poison Journal. 13 babies with botulism linked to infant formula, Nov 2025. https://www.foodpoisonjournal.com/food-poisoning-information/13-babies-with-botulism-linked-to-infant-formula